Infections caused by Staphylococcus aureus, particu larly those that are resistant to methicillin and all available βlactam antibiotics -the socalled methicillinresistant S. aureus (MRSA) infections -have been declared a public health imperative. A recent report from the Centers for Disease Con trol and Prevention 1 estimated that 18,650 per sons in the United States died from invasive MRSA infections in 2005. A new therapeutic approach to the management of these infections would therefore be welcome.
The development of new antibiotics to treat MRSA infections has slowed for complex reasons. 2 Some researchers have pointed to a lack of "new" microbial targets. Indeed, most antimicrobial agents currently in use are directed against bacte rial cellwall metabolism, the machinery of bac terial protein synthesis, or a biosynthetic pathway unique to bacteria. Targeting a pathway that is common to bacteria and humans may kill the bacteria but may also incur unacceptable adverse events.
Liu and colleagues 3 recently observed that the synthesis of staphyloxanthin, the carotenoid pig ment that bestows the golden yellow color of clinical isolates of S. aureus, can be greatly dimin ished by a candidate inhibitor of human squalene synthase; this agent was previously developed to inhibit cholesterol synthesis. The inhibitor is like ly to have few toxic effects, since only cholesterol synthesis is targeted and cholesterol is likely to be present in the serum or the diet. Liu et al. also observed that the human squalene synthase inhibitor greatly diminished staphyloxanthin bio synthesis in vitro. They inoculated mice intraperi toneally with a wildtype, pigmented S. aureus isolate called ATCC 27659 or an isogenic mutant that lacked the dehydrosqualene synthase gene. Only the mutant strain was cleared by the host. A comparison of experimental intranasal inocu lation showed that the rate and magnitude of colonization for the two strains did not differ. Liu et al. also showed that treatment of mice with the dehydrosqualene synthase inhibitor af ter intraperitoneal inoculation resulted in en hanced bacterial killing, as evidenced by lower bacterial counts in the mouse kidney.
The success of this approach is largely depen dent on a pathway (Fig. 1 ) used in the early steps of synthesis of both staphyloxanthin and squalene, which is a cholesterol precursor. Liu et al. posit that staphyloxanthin may be a critical virulence factor in S. aureus infections because of its ability to detoxify antibacterial molecular spe cies such as the superoxide anion, hydrogen per oxide, and hypo chlorous acid, which are gener ated mainly by neutrophils of the host's immune system.
The concept of countering pathogenicity by inhibiting the synthesis of a virulence factor is new. Whether it will be clinically applicable re quires further testing, possibly including the T h e ne w e ngl a nd jou r na l o f m e dic i ne targeting of other components of staphyloxan thin synthesis or other virulence factors, toxins, or adhesins. The relative importance of these fac tors remains to be seen. Many steps would be required to translate this observation for use in the clinical arena. Liu et al. studied just one strain of S. aureus; its relation ship to other currently circulating strains -epi demic MRSA strains in particular -is uncertain. Some clinical isolates do not produce staphylox anthin, which is inferred from their lack of yel low pigment on solid mediums. A more thorough characterization of the animal model used by Liu et al. would be informative. The decrease in bacteria surviving in the kidney after parenteral inoculation observed by Liu et al. is consistent with a therapeutic effect, but other organs and other routes of inoculation should be tested. Moreover, the effect of renal bacteria on survival varied among the animals studied; identifying the causes of this variation may help to guide further research.
Removing the Golden Coat of Staphylococcus aureus
S. aureus is a commensal bacterium; it colo nizes the skin and mucosal surfaces such as the nares, pharynx, and vagina. At any given time, approximately 25 to 40% of people are colonized with S. aureus. The mere presence of the organ ism in the nose or on the skin does not seem to provoke a host response; thus, the staphyloxan thin inhibitor used by Liu et al. had no effect on S. aureus in this setting.
Disease is produced by one of several mecha nisms (Fig. 2) . A breach in the mucosal barrier or skin may allow opportunistic multiplication of bacteria in the subcutaneous tissues and there by result in an infection of the skin or soft tis sue; invasive disease infrequently follows. Many neutrophils are recruited to the site of this event.
An inhibitor of staphyloxanthin synthesis may halt the progression of a recognized skin and softtissue infection. Another route of infection is through inhalation; infection may establish a primary pneumonia that may be necrotizing. A preceding infection with a virus such as influ enza may predispose persons to this form of in fection. It is uncertain whether the production of staphyloxanthin would influence this scenario. Occasionally, severe disease (e.g., a systemic toxinosis such as toxic shock syndrome) may occur without the migration of S. aureus from its superficial mucosal perch; one of a variety of toxins or superantigens that can initiate a cas cade of host responses may be secreted. It is unlikely that the enhanced killing of neutro phils would critically affect the course of such a toxinosis.
Although most S. aureus infections, on reach ing the bloodstream, are probably selflimited by host defense mechanisms, an intravascular infec tion or metastatic infection may occur. The intra peritoneal inoculation route used by Liu et al. most closely resembles invasive disease, and it is in this context that their approach, perhaps in combination with another antiinfective agent such as a conventional antibacterial compound, shows the most promise.
S. aureus is a dynamic species, endowed with an array of adhesins and virulence factors, and thus it facilely adapts to a variety of environ ments. Therefore, it seems unlikely that the ap proach used by Liu et al. will 
